Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial. (PubMed, Ann Oncol) - Oct 24, 2026 - "The addition of perioperative nivolumab to neoadjuvant GC did not improve outcomes and was associated with predictable toxicity. Exploratory analysis showed ctDNA was strongly prognostic."
Journal • P3 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
|
|
A Kotsakis; A Necchi; C Jeyamohan; D Bimbatti; G Schepisi; G Schinzari; G Sonpavde; G Steinberg; H Miyake; J E Gschwend; J J Oh; J Neely; J P Sade; J Zhang; M D Galsky; M Jacques; M S van der Heijden; Q Duong; S Gupta; S Panay; S Sarkar; S Vázquez Estévez; U De Giorgi
|